The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 23 April, approved omaveloxolone (Skyclarys), the first treatment for patients aged 16 and over, in the UK for a rare neurodegenerative movement disorder called Friedreich’s ataxia.
Friedreich’s ataxia is the most common type of hereditary ataxia (caused by genes a person has inherited). It is thought to affect at least 1 in every 50,000 people. Symptoms of Friedreich’s ataxia include problems with balance and movement, which get progressively worse over time.
This medicine is taken as an oral capsule…
